{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099631","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.513514+00:00","generated_at":"2026-05-17T23:32:21.495764+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M","bullets":["Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.","Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.","Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.","Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.","Company expects to provide update on first-line mCRC program by Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099631","json":"https://secwatch.observer/filing/0000950170-25-099631.json","markdown":"https://secwatch.observer/filing/0000950170-25-099631.md","text":"https://secwatch.observer/filing/0000950170-25-099631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/0000950170-25-099631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/crdf-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:32:21.495764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}